» Articles » PMID: 25388280

Prospective Evaluation of PBC-specific Health-related Quality of Life Questionnaires in Patients with Primary Sclerosing Cholangitis

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2014 Nov 13
PMID 25388280
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Primary biliary cirrhosis and Primary sclerosing cholangitis are autoimmune cholestatic liver diseases sharing a lot in common, including a significant impairment of patients' health-related quality of life HRQoL HRQoL in PBC is assessed with disease-specific PBC-40 and PBC-27 questionnaires. A PSC-specific questionnaire has not been developed. Neither PBC-40 nor PBC-27s applicability for PSC has been evaluated. We applied these three questionnaires for HRQoL assessment in a large homogenous cohort of PSC patients.

Patients And Methods: This cross-sectional study enrolled 102 Caucasian PSCs and 53 matched healthy controls and measured HRQoL using generic SF-36, and disease-specific (PBC-40/PBC-27) questionnaires.

Results: (i) SF-36. Most SF-36 domains were significantly lower in PSCs than controls. Physical Functioning and Mental Component Summary scores were significantly lower in female patients and correlated negatively with age but not with concurrent inflammatory bowel disease. Cirrhosis was associated with lower Physical Functioning, Role Physical, General Health, Vitality and Physical Component Summary. (ii) PBC-40 and PBC-27. Both tools showed similar HRQoL impairment scoring. Fatigue and Cognitive were impaired in female patients. Several correlations existed between HRQoL and laboratory parameters, including cholestatic tests and Itch. Cirrhosis correlated with Other symptoms and Fatigue PBC-40. (iii) PBC-40 vs PBC-27. Strong correlations among most domains of both questionnaires were seen, as well as between (iv) SF-36 vs PBC-40 or SF-36 vs PBC-27.

Conclusion: This is the first study directly comparing PBC-40, PBC-27 and SF-36 in PSC. PSC patients, especially females, show HRQoL impairment. PBC-40 and PBC-27 questionnaires could be of potential use for HRQoL assessment in PSC.

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.


Improving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial.

Uhlenbusch N, Bal A, Balogh B, Braun A, Geerts A, Hirschfield G BMC Psychiatry. 2023; 23(1):193.

PMID: 36964518 PMC: 10039546. DOI: 10.1186/s12888-023-04669-0.


A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients.

Kruk B, Milkiewicz M, Raszeja-Wyszomirska J, Milkiewicz P, Krawczyk M Orphanet J Rare Dis. 2022; 17(1):419.

PMID: 36397154 PMC: 9670364. DOI: 10.1186/s13023-022-02565-6.


PR3-ANCAs Detected by Third-Generation ELISA Predicts Severe Disease and Poor Survival in Primary Sclerosing Cholangitis.

Lopens S, Wunsch E, Milkiewicz M, Rober N, Zarske G, Nasser A Diagnostics (Basel). 2022; 12(11).

PMID: 36359524 PMC: 9689935. DOI: 10.3390/diagnostics12112682.


Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.

Wunsch E, Krause L, Gevers T, Schramm C, Janik M, Krawczyk M Liver Int. 2022; 43(2):381-392.

PMID: 36177700 PMC: 10091761. DOI: 10.1111/liv.15440.